Microbiome modulators in the treatment of infectious diseases: insights from clinical trials Authors: Shidong Wang, Chenjuan Wang, Linhua Shen, Mengjin Zhu, Jiannong Wu Published: 2024 Dear editor, Infectious diseases continue to pose a major threat to current global morbidity and mortality. Faced with this challenge, in addition to the application of traditional antimicrobial drugs, the development of microbiome engineering technology has opened up new avenues for treatment in recent years. Microbiome modulators mainly achieve anti-infective effects by strengthening barriers, increasing adhesion, inhibiting pathogens, competing for exclusion, synthesizing antibacterial substances, modifying toxins, and stimulating immune responses [1]. To explore its clinical significance, we analysed clinical trial data with the aim of providing insight into treatment strategies and research directions. In this study, we utilised the resources of open clinical trial databases to summarise the current status of clinical trials of microbiome modulators in the therapeutic area of infectious diseases.We designed a query strategy to perform an exhaustive search in the Informa database using “(Mechanism Of Action: Microbiome modulator) AND (Therapeutic Area: Infectious Disease)” as a keyword combination. Through screening, we finally identified 858 clinical trial records that met the criteria as of 7 September 2024. Microbiome modulators include probiotics, prebiotics, synbiotics, metaprobiotics, fecal microbiota transplantation (FMT), and lingiving biotherapeutic products (LBP) [2]. The annual distribution of the microbiome clinical trials showed that their numbers had increased significantly since 2012 and peaked in 2021 (see Fig. 1A for the specific annual number distribution). 563 clinical trials have been completed, and numerous phase IV clinical trials have been widely conducted, showing the importance of this treatment in clinical practice (see Fig. 1B for the specific phase of clinical trials). Clinical trials of microbiome modulators for the treatment of infectious diseases. (A) Annual distribution of clinical trials (2001–2024), excluding 106 studies missing start date. (B) Status distribution within phases. (C) Classification of clinical trials by type of disease treated. (D) Classification of clinical trials by type of pathogen treated Among the various systemic infections treated, the number of clinical trials used to treat respiratory infections was the highest (see Fig. 1C). Among respiratory infections, numerous viral infections still lack effective treatment.And the development of drugs for the treatment of respiratory infections has been made difficult by the wide variety of pathogens and increasing drug resistance.The diseases treated by microbiome modulators in this area include pneumonia, common cold, influenza, and new coronavirus infections, and the age groups involved cover children, adults, and the elderly.Exploring microbiome modulators as novel therapeutics is important to broaden the therapeutic pathway for respiratory infections and to address the issue of drug resistance.In terms of treating specific pathogens, C. difficile infections have been given high priority (see Fig. 1D). C. difficile is the leading cause of antibiotic-associated diarrhoea, with a recurrence rate of up to 20% [3]. Restoring the balance and function of the gut microbial community is essential for treating the disease and reducing recurrence rates, so microbiome modulators play an important role here.At the same time, we found fewer studies of microbial modulators for the treatment of Gram-negative-positive bacterial infections, either because current research focuses more on the treatment of such bacteria with antibiotics.It is worth noting that for the treatment of viruses, the highest number of occupations was for novel coronaviruses.This trend reflects the global emphasis and investment in new coronavirus research. It provides comprehensive coverage of all phases from prophylactic exposure to new coronaviruses to prognostic management.Changes in the gut microbiota have important implications for the serious consequences of novel coronavirus pneumonia, including in the pathogenesis of sepsis and acute respiratory distress syndrome [4]. Certain probiotics, such as Lactobacillus and Bifidobacterium, control inflammation by modulating immunity and controlling Treg, Th1/Th2 responses and inflammatory factor release [5]. The application of specific probiotics has emerged as a promising approach for the treatment of novel coronavirus. This study analysed the current status of clinical trials of microbiome modulators for the treatment of infectious diseases and found that they have a wide range of potential in a variety of diseases. And they have some unique advantages over conventional treatments.First, some anti-infective drugs are limited in the use of children and elderly patients due to concomitant adverse reactions. Children accounted for 27.7% and the elderly for 52.2% of the clinical trials, demonstrating both therapeutic safety and providing an effective complementary anti-infective treatment option for both populations. Second, microbiome modulators can directly regulate the status of microbial communities in the treatment of certain diseases, which is an ability that antibiotics do not have. For example, in the treatment of Clostridium difficile infection, antibiotics can temporarily control the condition but fail to fundamentally correct the intestinal microecological imbalance. In contrast, microbiome modulators can regulate the microbial community in a way that is both effective and relapse-proof.However, these clinical trial results also have some limitations, and first some targets for drug therapy remain unclear, which affects further exploration of efficacy.Second, given the complexity of infectious disease management, microbiome modulators often need to be co-administered, so it is particularly important to explore comprehensive treatment options in depth.It should not be overlooked that increasing antibiotic resistance is driving the search for additional therapeutic avenues.It is reasonable to believe that this treatment may become an important strategy for the treatment of infections in the future. Acknowledgements None. Author contributions SW: drafted the manuscript; CW and LS: collected the related studies; MZ: review & editing; JW: revised the manuscript. Funding This work was supported by Basic Public Welfare Research Programme of Zhejiang Province(LGD21H290001) and National Natural Science Foundation of China(82174178). Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors of this article agree to publish. Competing interests The authors declare there is no conflict of interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.